Question explored with the scientific record
does mebendazole assist in controlling cancer?
The short version: mebendazole shows real anti-cancer activity in lab dishes and mice, but the only human trial in advanced cancer found no benefit and even signs of harm.
The strongest evidence for mebendazole as a cancer drug comes from preclinical work. In colon cancer cells, it cuts viability by 40-80% and slows mouse tumors by about 50-70% [2]. A 2025 study on a specific leukemia (CML blast crisis) found that mebendazole disrupts a core set of transcription factors driving the disease and suppressed it in mice [3]. A 2026 glioblastoma study showed mebendazole improved survival in mice, especially when combined with a genetic change that made tumors more sensitive [4]. These are real signals.
But the only human trial tells a different story. A phase 2a study in 2021 gave dose-adjusted mebendazole to 10 patients with advanced gastrointestinal cancer who had run out of standard options. The drug was safe at up to 4 grams a day. But all eight patients who could be evaluated had progressive disease at 8 weeks [1]. Four of them met criteria for hyperprogression, meaning their tumors grew faster than expected [1]. The trial was single-arm and small, so it cannot prove mebendazole caused the progression, but it certainly did not help.
| Evidence type | What it shows | Limitation |
|---|---|---|
| Cell and mouse studies | 40-80% cell kill, 50-70% tumor slowdown [2] | Does not predict human response |
| CML mouse model | Suppressed leukemia via transcription factor disruption [3] | Only one leukemia subtype |
| GBM mouse model | Improved survival, especially with ATAT1 deletion [4] | Genetic manipulation not available in patients |
| Human phase 2a trial | 0 of 8 patients responded; 4 showed possible hyperprogression [1] | Very small, no control group |
The gap between mouse and human is enormous. Many drugs that work in mice fail in people. The human evidence here is not just thin — it is negative. A single small trial does not close the door, but it puts the burden squarely back on the people promoting mebendazole for cancer to run a proper controlled trial.
My call: mebendazole has plausible anti-cancer mechanisms and strong preclinical data, but the only human trial found no benefit and a signal of possible harm. It should not be used for cancer outside a clinical trial. Confidence: moderate.
Sources used 4
-
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
In a phase 2a single-arm study, individualized dose-adjusted mebendazole up to 4 g/day was safe and well tolerated in advanced gastrointestinal cancer patients refractory to standard treatment, but all eight evaluable patients had progressive disease at 8 weeks.
DOI: 10.1038/s41598-021-88433-y -
Repurposing A Common Anthelmintic Drug Mebendazole for Colon Cancer Therapy
A review of preclinical evidence suggests that mebendazole and other benzimidazole anthelmintics inhibit colon cancer cell growth and tumor progression through microtubule disruption, apoptosis, and anti-angiogenic mechanisms, supporting potential repurposing.
DOI: 10.31579/2640-1053/254 -
The transcriptional regulatory circuit as a driver and therapeutic target in CML blast crisis
The study identifies a four-transcription-factor core regulatory circuit (MEF2C, MYB, MEIS1, ZEB2) driving transcriptional and chromatin remodeling in CML blast crisis, elucidates how this circuit promotes BP progression through GLUL-mediated purine metabolism and Rho GTPase sig…
DOI: 10.1101/2025.11.02.686161 -
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Targeting ATAT1-driven α-tubulin K40 acetylation suppresses glioblastoma invasion and proliferation, reduces oncogenic signaling and therapy resistance, and enhances sensitivity to microtubule depolymerizers and temozolomide, improving survival in preclinical GBM models.
DOI: 10.64898/2026.06.15.732342